SCHEMBL3207442

SCHEMBL3207442

O=S(=O)(c1ccc(Cl)c(Cl)c1)N1CCN(c2ccccc2F)CC1

nearest known ligand 0.74

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.74
SMN1; SMN2 Q16637 7/20 0.74
HTT P42858 4/20 0.74
HSD11B1 P28845 3/20 0.71
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
TP53 P04637 4/20 0.63
HPGD P15428 1/20 0.63
TSHR P16473 4/20 0.62
MAPK1 P28482 2/20 0.62
ALDH1A1 P00352 4/20 0.62
MAPT P10636 2/20 0.61
PSMD14 O00487 1/20 0.60
HSD17B10 Q99714 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3201922 0.85 HSD11B1 (0.69) LMNASMN1; SMN2HTTHSD11B1MEN1
SCHEMBL3214231 0.83 HSD11B1 (1.00) LMNASMN1; SMN2HTTHSD11B1MEN1
SCHEMBL709967 0.81 HSD11B1 (0.70) LMNASMN1; SMN2HTTHSD11B1MEN1
SCHEMBL3222472 0.80 HSD11B1 (0.73) LMNASMN1; SMN2HTTHSD11B1MEN1
SCHEMBL13743134 0.80 LMNA (0.61) LMNASMN1; SMN2HTTHSD11B1MEN1
SCHEMBL12793329 0.80 POLB (0.76) LMNASMN1; SMN2HTTHSD11B1MEN1
SCHEMBL3216764 0.79 ALDH1A1 (0.64) LMNASMN1; SMN2HTTHSD11B1KMT2A
SCHEMBL3219644 0.77 MAPK1 (0.60) LMNASMN1; SMN2HTTHSD11B1MEN1
SCHEMBL4486893 0.76 HSD11B1 (1.00) LMNASMN1; SMN2HTTHSD11B1MEN1
SCHEMBL4465327 0.75 CNR1 (0.68) LMNASMN1; SMN2HTTHSD11B1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
EP-1981848-A2 11-BETA HSD1 INHIBITORS Wyeth (US) 2008-10-22 EP disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
WO-2007092435-A2 11-BETA HSD1 INHIBITORS WYETH (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 LMNA 3748/4885SMN1; SMN2 3575/4885HTT 1959/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 LMNA 3681/4885SMN1; SMN2 3686/4885HTT 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.